Abstract:Backgrounds Non‐small cell lung carcinoma (NSCLC) is a common type of lung cancer. Prior investigations have elucidated the pivotal role of miR‐29b‐3p in restraining tumor growth and metastasis. Nonetheless, it remains to be determined whether miR‐29b‐3p can effectively suppress NSCLC progression and enhance the sensitivity of NSCLC cells to cisplatin. This investigation sought to determine the mechanism by which miR‐29b‐3p inhibited the advancement of NSCLC and mitigated resistance to cisplatin. Methods We initially assessed miR‐29b‐3p and VEGF levels in NSCLC tissues and cell lines. Next, miR‐29b‐3p expression was elevated in NSCLC cell lines H1975 and A549 by overexpression plasmid transfection. Following this, a sequence of molecular biology experiments was conducted to evaluate the impact of miR‐29b‐3p on the biological behaviors of NSCLC cells and their resistance to cisplatin. Additionally, we predicted VEGF was a target gene of miR‐29b‐3p by bioinformatics analysis. We next employed western blot to evaluate the protein expression of Nrf2 and HO‐1 in NSCLC cells. Finally, we elucidated the effects of VEGF and Nrf2/HO‐1pathway on NSCLC progression and cisplatin resistance by in vitro assays. Results In comparison to paracancerous tissues and human normal lung epithelial cells, the expression of miR‐29b‐3p was notably reduced and VEGF expression was clearly elevated in NSCLC tissues and cells. Moreover, miR‐29b‐3p upregulated obviously suppressed the biological activities of NSCLC cells and increased their sensitivity to cisplatin. Furthermore, in NSCLC cells, miR‐29b‐3p bound to VEGF and negatively regulate its transcription. Additionally, miR‐29b‐3p overexpression also inhibited the Nrf2/HO‐1 signaling pathway. Finally, the overexpression of VEGF and the activation of the Nrf2/HO‐1 pathway reversed miR‐29b‐3p‐mediated inhibitory effect on biological behaviors of NSCLC cells and increased the cisplatin resistance. Conclusion Our findings indicate that miR‐29b‐3p impedes NSCLC cells' biological behaviors and augments their sensitivity to cisplatin by targeting VEGF to modulate the Nfr2/HO‐1 signaling pathway.

Author Correction: MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway

Mir-488 Inhibits Proliferation And Cisplatin Sensibility In Non-Smallcell Lung Cancer (Nsclc) Cells By Activating The Eif3a-Mediated Ner Signaling Pathway

MicroRNA-191 Modulates Cisplatin-Induced DNA Damage Response by Targeting RCC2.

LINC02389/miR-7-5p Regulated Cisplatin Resistance of Non-Small-Cell Lung Cancer via Promoting Oxidative Stress

Mir-194 Inhibits the Proliferation, Invasion, Migration, and Enhances the Chemosensitivity of Non-Small Cell Lung Cancer Cells by Targeting Forkhead Box A1 Protein

miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression

DNA Damage Responsive Mir-33B-3p Promoted Lung Cancer Cells Survival and Cisplatin Resistance by Targeting P21waf1/cip1

Alterations of microRNAs in Cisplatin-resistant Human Non-small Cell Lung Cancer Cells (A549/DDP)

miRNA-378 reverses chemoresistance to cisplatin in lung adenocarcinoma cells by targeting secreted clusterin

MiR-192 Confers Cisplatin Resistance by Targeting Bim in Lung Cancer

Attenuation of deregulated miR-369-3p expression sensitizes non-small cell lung cancer cells to cisplatin via modulation of the nucleotide sugar transporter SLC35F5

miR-181b inhibits chemoresistance in cisplatin-resistant H446 small cell lung cancer cells by targeting Bcl-2

MicroRNA-218 Regulates Cisplatin (DPP) Chemosensitivity in Non-Small Cell Lung Cancer by Targeting RUNX2

miR‐29b‐3p targetedly regulates VEGF to inhibit tumor progression and cisplatin resistance through Nrf2/HO‐1 signaling pathway in non‐small cell lung cancer

Mir‑144‑3p Regulates the Resistance of Lung Cancer to Cisplatin by Targeting Nrf2.

Mir-503 Regulates the Resistance of Non-Small Cell Lung Cancer Cells to Cisplatin by Targeting Bcl-2.

Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1

The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells

miR-185-5p May Modulate the Chemosensitivity of LUSC to Cisplatin via Targeting PCDHA11: Multi-omics Analysis and Experimental Validation

Exosome-Reversed Chemoresistance to Cisplatin in Non-Small Lung Cancer Through Transferring miR-613

Targeted Inhibition of miR-221/222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells.